Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.

Deans ZC, Tull J, Beighton G, Abbs S, Robinson DO, Butler R.

Genet Test Mol Biomarkers. 2011 Nov;15(11):777-83. doi: 10.1089/gtmb.2010.0239. Epub 2011 Aug 18.

PMID:
21851273
2.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

3.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
4.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
5.

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.

Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN.

Arch Pathol Lab Med. 2009 Oct;133(10):1600-6. doi: 10.1043/1543-2165-133.10.1600. Review.

PMID:
19792050
6.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
7.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
8.

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A.

Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30. Review.

PMID:
19117687
9.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Review.

10.

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R.

Cancer Treat Rev. 2015 Sep;41(8):653-9. doi: 10.1016/j.ctrv.2015.05.008. Epub 2015 May 21. Review.

11.

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.

Chen J, Ye Y, Sun H, Shi G.

Cancer Chemother Pharmacol. 2013 Jan;71(1):265-72. doi: 10.1007/s00280-012-2005-9. Epub 2012 Oct 23. Review.

PMID:
23090619
13.

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL.

Cancer. 2013 Feb 15;119(4):714-21. doi: 10.1002/cncr.27804. Epub 2012 Sep 12. Review.

14.

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

Stintzing S, Heinemann V, Moosmann N, Hiddemann W, Jung A, Kirchner T.

Dtsch Arztebl Int. 2009 Mar;106(12):202-6. doi: 10.3238/arztebl.2009.0202. Epub 2009 Mar 20. Review.

15.

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365. Review.

16.

Impact of cetuximab in current treatment of metastatic colorectal cancer.

Sotelo Lezama MJ, Sastre Valera J, Díaz-Rubio García E.

Expert Opin Biol Ther. 2014 Mar;14(3):387-99. doi: 10.1517/14712598.2014.883376. Epub 2014 Jan 30. Review.

PMID:
24479733
17.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
18.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

19.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
20.

The role of cetuximab as first-line treatment of colorectal liver metastases.

Jones C, Taylor MA, McWilliams B.

HPB (Oxford). 2013 Jan;15(1):11-7. doi: 10.1111/j.1477-2574.2012.00591.x. Epub 2012 Oct 17. Review.

Items per page

Supplemental Content

Write to the Help Desk